young rabbit complement (Cedarlane)
Structured Review

Young Rabbit Complement, supplied by Cedarlane, used in various techniques. Bioz Stars score: 95/100, based on 43 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+complement/Baby+Rabbit+Complement%2C+Sterile%2C+Frozen/pm39242614-273-5-9
Average 95 stars, based on 43 article reviews
Images
1) Product Images from "A nonadjuvanted HLA-restricted peptide vaccine induced both T and B cell immunity against SARS-CoV-2 spike protein."
Article Title: A nonadjuvanted HLA-restricted peptide vaccine induced both T and B cell immunity against SARS-CoV-2 spike protein.
Journal: Scientific reports
doi: 10.1038/s41598-024-71663-1
Figure Legend Snippet: Fig. 4. In vivo immune responses of injected UC peptides and complement activity of immunized serum. (a) BALB/c mice were intramuscularly administered 3 doses of 50 µg of UC-100 (n = 3) or 400 µg of UC-152 (n = 4) 14 days apart. (b–d) The serum of UC-100 mice was collected pre-(Day-1) and posttreatment (Day41) and tested in duplicate and represented as the mean for the levels of (b) total IgG; (c) specific IgG against UC-100 peptide; (d) specific IgG against SARS-CoV-2 spike trimer protein. (e–g) The serum of UC-152 mice was collected pre-(Day-1) and posttreatment (Day41) and tested in duplicate and represented as the mean for the levels of (e) total IgG; (f) specific IgG against UC-152 peptide; (g) specific IgG against SARS-CoV-2 spike trimer protein. (h,i) Antibody-mediated complement activity was tested in duplicate and is represented as the mean for pre- and postserum of mice vaccinated with UC-100 and UC-152 peptides, respectively. The complement activity was expressed as the IC50 of cytotoxicity of the (h) UC-100-vaccinated group and (i) UC-152-vaccinated group. Significant differences are indicated by asterisks (unpaired one-tailed Student’s t test; *p < 0.05, **p < 0.01, ***p < 0.001).
Techniques Used: In Vivo, Injection, Activity Assay, One-tailed Test
Figure Legend Snippet: Fig. 5. In vivo immune responses of oral UC peptides and complement activity of immunized serum. (a) BALB/c mice (n = 5) were orally administered 3 doses of 200 µg UC-100 14 days apart. (b–d) The serum of UC-100 mice was collected pre-(Day-1) and posttreatment (Day 41) and tested in duplicate and represented as the mean for the levels of (b) total IgG; (c) specific IgG against UC-100 peptide; (d) specific IgG against SARS-CoV-2 spike trimer protein; (e) The antibody-mediated complement activity was tested in duplicate and represented as the mean for pre- and postserum of mice vaccinated with UC-100. The complement activity was expressed as the IC50 of cytotoxicity. (f,g) The serum of UC-100 mice was collected pre-(Day-1) and posttreatment (Day 41) and tested in duplicate and represented as the mean for the levels of (f) total IgA and (g) specific IgA against UC-100 peptide. Significant differences are indicated by asterisks (unpaired one-tailed Student’s t test; *p < 0.05, **p < 0.01, ***p < 0.001).
Techniques Used: In Vivo, Activity Assay, One-tailed Test
Figure Legend Snippet: Fig. 6. Summary of the SARS-CoV-2 HLA-restricted peptide T-cell vaccine. The possible mechanistic immune response to HLA-restricted peptides has been elucidated. The 9-mer UC peptides can be primed onto both HLA class I and II molecules, and the immune response is triggered for both humoral and cellular immunity. Through HLA class I molecule binding, CTLs can be activated, and an increase in IFN-γ cytokines and specific lytic activity have been observed. Through HLA class II molecule binding, B-cells are activated, and specific antibodies are produced in accordance with complement cytotoxicity activity.
Techniques Used: Binding Assay, Activity Assay, Produced
Related Articles
Incubation:Article Title: Neutrophils, not macrophages, aid phage-mediated control of pulmonary Pseudomonas aeruginosa infection Article Snippet: .. In a second incubation step to initiate the phagocytosis process, Article Title: Development of an anti-rat complement C2 antibody that improves renal outcome in a rat kidney transplant model Article Snippet: .. Next, samples and calibration curve diluted in TBS supplemented with 2 mM CaCl 2 , 10 μg/mL of the new anti-rat C2 antibody and 10%, Article Title: Development of an anti-rat complement C2 antibody that improves renal outcome in a rat kidney transplant model Article Snippet: .. Next, samples and calibration curve diluted in TBS supplemented with 2 mM CaCl2, 10 μg/mL of the new anti-rat C2 antibody and 10%, Article Title: Proteins comprising CD3 antigen binding domains and uses thereof Article Snippet: .. Antibodies were added to target cells and incubated for 30 minutes at 37° C. After incubation, 15-20% (stock concentration) of rabbit complement (Cedarlane cat. #CL3441-S) and Concentration Assay:Article Title: Proteins comprising CD3 antigen binding domains and uses thereof Article Snippet: .. Antibodies were added to target cells and incubated for 30 minutes at 37° C. After incubation, 15-20% (stock concentration) of rabbit complement (Cedarlane cat. #CL3441-S) and Bacteria:Article Title: Rationally designed minimized TbpB confers broad protection against meningococcal infection Article Snippet: The next day, bacteria was restreaked onto fresh GC-Isovitalex plates containing 100 μmol/L deferoxamine mesylate salt (Sigma, cat. D9533) for 4 h. Bacteria were collected off the plates using a Dacron swab, resuspended in PBS++, and OD measured. .. Assay was set up in 40 μL total volume using ∼500 bacteria suspended in PBS++, 10% baby rabbit complement (Cedarlane, CL3441-S100) and 2-fold serial dilutions of CDC Assay:Article Title: CAR-T cells generated in vivo for the targeted treatment of myocardial fibrosis. Article Snippet: Myocardial fibrosis is an irreversible pathological consequence that occurs as various heart diseases progress to their end stages.. Currently, no effective therapeutic strategies have been established in clinical practice for its management.. The development of T-cell therapy offers promising and innovative opportunities for the treatment of myocardial fibrosis. Cell Culture:Article Title: CAR-T cells generated in vivo for the targeted treatment of myocardial fibrosis. Article Snippet: Myocardial fibrosis is an irreversible pathological consequence that occurs as various heart diseases progress to their end stages.. Currently, no effective therapeutic strategies have been established in clinical practice for its management.. The development of T-cell therapy offers promising and innovative opportunities for the treatment of myocardial fibrosis. |
